Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Small molecule-based targeting of chromatin regulatory factors has emerged as a promising
therapeutic strategy in recent years. The development and ongoing clinical evaluation of …

MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an
approach to exploit cancer vulnerabilities. Here, we develop proteolysis targeting chimera …

The two tandem bromodomains of the BET (bromodomain and extraterminal domain)
proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both …

Cancer arises from genetic alterations that invariably lead to dysregulated transcriptional
programs. These dysregulated programs can cause cancer cells to become highly …

The MYC oncogene encodes a transcription factor, MYC, whose broad effects make its
precise oncogenic role enigmatically elusive. The evidence to date suggests that MYC …

The incidence of biliary tract cancer (BTC), including intrahepatic (ICC) and extrahepatic
(ECC) cholangiocarcinoma and gallbladder cancer, has increased globally; however, no …

Gene expression in mammals is regulated by noncoding elements that can affect physiology
and disease, yet the functions and target genes of most noncoding elements remain …